Abstract
Based on the improved insight into the mechanism of blood coagulation in vivo, recombinant factor VIIa (rFVIIa) has been developed as a pro-haemostatic agent. It has been shown that this treatment is effective in patients with haemophilia and an inhibiting antibody against a coagulation factor. Administration of rFVIIa can be effective in the treatment of bleeding episodes and the prevention of perioperative blood loss in a number of other coagulation disorders as well. Initial clinical studies indicate that administration of rFVIIa may also reduce blood loss in patients with severe bleeding without pre-existent abnormalities in blood coagulation, but this requires confirmation in additional clinical trials
| Original language | Dutch |
|---|---|
| Pages (from-to) | 2534-2537 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 146 |
| Issue number | 52 |
| Publication status | Published - 2002 |